PURPOSE OF REVIEW: This review focuses on our current understanding of fate decisions in bipotent megakaryocyte-erythroid progenitors (MEPs). Although extensive research has been carried out over decades, our understanding of how MEP commit to the erythroid versus megakaryocyte fate remains unclear. RECENT FINDINGS: We discuss the isolation of primary human MEP, and focus on gene expression patterns, epigenetics, transcription factors and extrinsic factors that have been implicated in MEP fate determination. We conclude with an overview of the open debates in the field of MEP biology. SUMMARY: Understanding MEP fate is important because defects in megakaryocyte and erythrocyte development lead to disease states such as anaemia, thrombocytopenia and leukaemia. MEP also represent a model system for studying fundamental principles underlying cell fate decisions of bipotent and pluripotent progenitors, such that discoveries in MEP are broadly applicable to stem/progenitor cell biology.
PURPOSE OF REVIEW: This review focuses on our current understanding of fate decisions in bipotent megakaryocyte-erythroid progenitors (MEPs). Although extensive research has been carried out over decades, our understanding of how MEP commit to the erythroid versus megakaryocyte fate remains unclear. RECENT FINDINGS: We discuss the isolation of primary human MEP, and focus on gene expression patterns, epigenetics, transcription factors and extrinsic factors that have been implicated in MEP fate determination. We conclude with an overview of the open debates in the field of MEP biology. SUMMARY: Understanding MEP fate is important because defects in megakaryocyte and erythrocyte development lead to disease states such as anaemia, thrombocytopenia and leukaemia. MEP also represent a model system for studying fundamental principles underlying cell fate decisions of bipotent and pluripotent progenitors, such that discoveries in MEP are broadly applicable to stem/progenitor cell biology.
Authors: Pekka Jaako; Johan Flygare; Karin Olsson; Ronan Quere; Mats Ehinger; Adrianna Henson; Steven Ellis; Axel Schambach; Christopher Baum; Johan Richter; Jonas Larsson; David Bryder; Stefan Karlsson Journal: Blood Date: 2011-10-11 Impact factor: 22.113
Authors: Hiroshi Kawada; Tatsuya Ito; Pamela N Pharr; Demetri D Spyropoulos; Dennis K Watson; Makio Ogawa Journal: Int J Hematol Date: 2001-06 Impact factor: 2.490
Authors: Andre M Pilon; Subramanian S Ajay; Swathi Ashok Kumar; Laurie A Steiner; Praveen F Cherukuri; Stephen Wincovitch; Stacie M Anderson; James C Mullikin; Patrick G Gallagher; Ross C Hardison; Elliott H Margulies; David M Bodine Journal: Blood Date: 2011-09-06 Impact factor: 22.113
Authors: K Kaushansky; S Lok; R D Holly; V C Broudy; N Lin; M C Bailey; J W Forstrom; M M Buddle; P J Oort; F S Hagen Journal: Nature Date: 1994-06-16 Impact factor: 49.962
Authors: Elisabeth F Heuston; Cheryl A Keller; Jens Lichtenberg; Belinda Giardine; Stacie M Anderson; Ross C Hardison; David M Bodine Journal: Epigenetics Chromatin Date: 2018-05-28 Impact factor: 4.954
Authors: Dorin-Mirel Popescu; Rachel A Botting; Emily Stephenson; Kile Green; Simone Webb; Laura Jardine; Emily F Calderbank; Krzysztof Polanski; Issac Goh; Mirjana Efremova; Meghan Acres; Daniel Maunder; Peter Vegh; Yorick Gitton; Jong-Eun Park; Roser Vento-Tormo; Zhichao Miao; David Dixon; Rachel Rowell; David McDonald; James Fletcher; Elizabeth Poyner; Gary Reynolds; Michael Mather; Corina Moldovan; Lira Mamanova; Frankie Greig; Matthew D Young; Kerstin B Meyer; Steven Lisgo; Jaume Bacardit; Andrew Fuller; Ben Millar; Barbara Innes; Susan Lindsay; Michael J T Stubbington; Monika S Kowalczyk; Bo Li; Orr Ashenberg; Marcin Tabaka; Danielle Dionne; Timothy L Tickle; Michal Slyper; Orit Rozenblatt-Rosen; Andrew Filby; Peter Carey; Alexandra-Chloé Villani; Anindita Roy; Aviv Regev; Alain Chédotal; Irene Roberts; Berthold Göttgens; Sam Behjati; Elisa Laurenti; Sarah A Teichmann; Muzlifah Haniffa Journal: Nature Date: 2019-10-09 Impact factor: 69.504